Anuh Pharma's Strong Financial Performance Garners 'Buy' Recommendation from MarketsMOJO

Anuh Pharma, a smallcap pharmaceutical company, has recently caught the attention of investors as its stock has been upgraded to a 'Buy' by MarketsMOJO on May 13, 2024. This upgrade comes as the company has shown strong financial performance and positive results in the past few quarters. One of the key factors contributing to the 'Buy' recommendation is the company's low Debt to Equity ratio, which is currently at 0 times. This indicates a healthy financial position and stability for the company. Additionally, Anuh Pharma has reported a growth in Net Profit of 38.18% and has declared positive results for the last three consecutive quarters. The company's performance in the last quarter has been particularly impressive, with PBT LESS OI(Q) at Rs 21.65 cr, PAT(Q) at Rs 19.11 cr, and NET SALES(Q) at Rs 172.10 cr. This has led to a Mildly Bullish range for the stock, with technical indicators such as MACD, Bollinger Band, and KST all showing bullish signals. Anuh Pharma also has a Very Attractive valuation with a ROE of 21.2 and a 4.5 Price to Book Value. The stock is currently trading at a fair value compared to its historical valuations, making it an attractive investment opportunity. In the past year, the stock has generated a return of 163.39%, while its profits have risen by 53%. This gives the company a PEG ratio of 0.4, indicating its strong performance in the market. However, there are some risks to consider when investing in Anuh Pharma. Despite its size, domestic mutual funds hold only 0% of the company, which could suggest that they are not comfortable with the current price or the business. As mutual funds have the capability to conduct in-depth research, this could be a red flag for potential investors. Overall, Anuh Pharma has shown a market-beating performance with its stock generating a return of 163.39% in the last year, significantly higher than the market (BSE 500) returns of 31.64%. With its strong financials and positive results, the company is poised for growth and presents a promising investment opportunity for those looking to invest in the pharma industry.